Study S000480

A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial

ClinicalTrials.gov record

Registration

Registration: NCT05931367
Acronym: TRIUMPH-4
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 445
Start: 2023-08-01
Primary completion: 2025-11-14
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight; Osteo Arthritis Knee
Interventions: DRUG:Retatrutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:J1I-MC-GZBN; OTHER:2023-503660-17-00; NIH:2023

Registered primary outcomes

Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score [Baseline, Week 68]
Percent Change from Baseline in Body Weight [Baseline, Week 68]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.